Needham & Company analyst Serge Belanger reiterated a Hold rating on Clearside Biomedical (NASDAQ: CLSD), following the company's announcement its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE